TrialNeuro-oncology2022

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Ami V Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.